Nanoparticulate Olmesartan Medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them

The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesarta...

Full description

Saved in:
Bibliographic Details
Main Authors PONGRACZ, KATALIN, FILIPCSEI, GENOVEVA, OTVOS, ZSOLT, DARVAS, FERENC
Format Patent
LanguageEnglish
Published 09.02.2012
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.
AbstractList The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.
Author FILIPCSEI, GENOVEVA
DARVAS, FERENC
OTVOS, ZSOLT
PONGRACZ, KATALIN
Author_xml – fullname: PONGRACZ, KATALIN
– fullname: FILIPCSEI, GENOVEVA
– fullname: OTVOS, ZSOLT
– fullname: DARVAS, FERENC
BookMark eNqNjL0KAjEQhFNo4d87LNgqmBPtD1Fs1EbrY7nb8wLJbkhy4BP43ObAxs5q-JiZb6pGLEwT9b4ii8eQTN1bTAQ36yhmRoYLNfISZyzU4rxEk4xwXIEPUlOM0EqA1FFmygYc2oEDSQvIDfgOg8Oa-izHX0kGTmjY8HO4uLkat2gjLb45U8vT8X44r8lLRdFnC1Oqykex0Ztir3dal3r73-oDD4tP0A
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID AU2010261511A1
GroupedDBID EVB
ID FETCH-epo_espacenet_AU2010261511A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:56:47 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_AU2010261511A13
Notes Application Number: AU20100261511
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20120209&DB=EPODOC&CC=AU&NR=2010261511A1
ParticipantIDs epo_espacenet_AU2010261511A1
PublicationCentury 2000
PublicationDate 20120209
PublicationDateYYYYMMDD 2012-02-09
PublicationDate_xml – month: 02
  year: 2012
  text: 20120209
  day: 09
PublicationDecade 2010
PublicationYear 2012
RelatedCompanies DRUGGABILITY TECHNOLOGIES IP HOLDCO (JERSEY) LIMITED
RelatedCompanies_xml – name: DRUGGABILITY TECHNOLOGIES IP HOLDCO (JERSEY) LIMITED
Score 2.8417115
Snippet The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Nanoparticulate Olmesartan Medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20120209&DB=EPODOC&locale=&CC=AU&NR=2010261511A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIDSJ4vrp_ZhyNauDGHrkE32NlKb4GBLy1bRv8C_20u6an3ZWy7hDpJwubvkdxeA27jFY4MmVLcYs3Qbm7pHXaZz7lKKLoVlOzLfeTB0-xP7eepMa7Aoc2FUndBPVRwRNeoN9T1X53X2d4kVKGzl-j6eY1f6FI7bgbaJjg0M5VueFnTbvVEURL7m-xhJasMX9ehrSuttdDBW2kFH-kECwHqvXZmXklWNSngIuyOUJ_IjqDHRgH2__HutAXuDzZM3Njfatz6GbzwKMcZdqXoZyEoimU6ANBUEGdKvdDlfEAkSL5FYdyQrEgEI-qYEfT2kWVHtOxWSXrGUEyoSkr1X77b_CSESzl58JCFZlidwE_bGfl_HCc1-12_WmVRnb51CXaSCnQExk9hhZmLZ1KA2p6Znuo8Jd2KGu0Rdl59Dc5uki-3Dl3Agd0RBnL0m1PPVB7tCC57H12rhfwB_jaTh
link.rule.ids 230,309,783,888,25578,76884
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbosYP1CaaPbnIPsMeiIENMpWvGDC8kc61kQS6BWb0L_Dv9tqB4gtvvS13SXu53v3auyvAbVTlkUFjqluMWbqNQ92jLtM5dynFkMKyHVnv3O254ch-GjvjAszWtTCqT-inao6IFvWG9p6p_Tr9O8QKVG7l8j6a4qfkoT2sB9oKHRsI5aueFjTrrUE_6Pua7yOS1Hov6tLXlN7baCBW2sEguyY77bdem7IuJd10Ku0D2B2gPJEdQoGJMpT89dtrZdjrrq68cbiyvuURfONWiBh3ofplICvpy3ICpKkgyJB8JfPpjMgk8XUm1h1J80IAgrEpwVgPaZZ3-06EpBcs4YSKmKTvm2fb_4QQmc6ePyQhWebHcNNuDf1QxwlNftdv0hhtzt46gaJIBDsFYsaRw8zYsqlBbU5Nz3RrMXcihlqirsvPoLJN0vn239dQCofdzqTz2Hu-gH2pHZXu7FWgmC0-2CV68yy6Ukr4AWS9p9E
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Nanoparticulate+Olmesartan+Medoxomil+compositions%2C+process+for+the+preparation+thereof+and+pharmaceutical+compositions+containing+them&rft.inventor=PONGRACZ%2C+KATALIN&rft.inventor=FILIPCSEI%2C+GENOVEVA&rft.inventor=OTVOS%2C+ZSOLT&rft.inventor=DARVAS%2C+FERENC&rft.date=2012-02-09&rft.externalDBID=A1&rft.externalDocID=AU2010261511A1